Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7297089 · 1 trial · 2 indications
Adverse event severity graded according to NCI CTCAE v5.0
| Arm | Type | Description |
|---|---|---|
| Arm A Flat Dose Escalation: RO7297089 | EXPERIMENTAL | Participants in Arm A will receive the target dose of RO7297089 as a flat dose at each scheduled study drug administration visit |
| Arm B Split Dose Escalation: RO7297089 | EXPERIMENTAL | Participants in Arm B will receive the first target dose of RO7297089 as a split dose divided over two days (Days 1 and 2). The full target dose will be administered at subsequent study drug administration visits. |
| Arm C Step Dose Escalation: RO7297089 | EXPERIMENTAL | No participants enrolled. Enrollment for the GO41582 study was stopped in July 2021 due to limited activity as a single agent which did not meet the Sponsor's internal criteria for further clinical development. |
| Phase I Expansion Stage: RO7297089 | EXPERIMENTAL | No participants enrolled. Enrollment for the GO41582 study was stopped in July 2021 due to limited activity as a single agent which did not meet the Sponsor's internal criteria for further clinical development. |
| Name | Type | Description |
|---|---|---|
| RO7297089 | DRUG | RO7297089 will be given via intravenous (IV) infusion |
Inclusion Criteria * Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 * Life expectancy of at least 12 weeks * R/R MM for which no established therapy for MM is appropriate and available or be intolerant to those established therapies * Measurable disease Exclusion criteria: ...
Top 20 of 25 competitors
RO7297089 is an investigational small molecule being developed for the treatment of refractory multiple myeloma. It is also being studied in patients with relapsed multiple myeloma. The drug is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
RO7297089 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting clinical trials to evaluate the safety and pharmacokinetics of this investigational drug in patients with relapsed or refractory multiple myeloma.
RO7297089 is in Phase 1 clinical development. A Phase 1 study evaluating escalating doses of the drug in patients with relapsed or refractory multiple myeloma has been completed. The drug is investigational and has not received regulatory approval.
RO7297089 has one completed clinical trial, identified as NCT04434469. This Phase 1 study evaluated the safety and pharmacokinetics of escalating doses of RO7297089 in patients with relapsed or refractory multiple myeloma. The trial enrolled 27 participants across Australia, Belgium, Denmark, and Norway.
RO7297089 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development for the treatment of refractory and relapsed multiple myeloma. The completed Phase 1 trial focused on safety and pharmacokinetics, and further studies would be needed for regulatory approval.